Clinical research is an important component of increasing medical knowledge, advancing veterinary practice, and improving animal health.
The OSU College of Veterinary Medicine offers clinical trials of new treatments and procedures in a variety of areas including oncology, cardiology, orthopedic surgery, and more. These trials will help to develop future treatments and diagnostic tools that are both safe and effective.
Answers to frequently asked questions about clinical trials can be found here. For information about a specific trial, please contact the individual at the bottom of each trial summary below.
All clinical trials in the Lois Bates Acheson Veterinary Teaching Hospital undergo prior review and approval by IACUC. The following are current, open clinical trials that are seeking participants.
The hospital is a member of the Comparative Oncology Trials Consortium (COTC), a network of twenty academic oncology centers, centrally managed by the National Institute of Health, that design and conduct clinical trials in dogs with cancer in order to assess new therapies.
Canine Patients with Naïve Multi-centric Lymphoma
Sulforaphane (SFN) is a natural compound found in cruciferous vegetables such as broccoli. Sulforaphane has been shown to play a powerful role in tumor suppression. This study will investigate SFN supplementation in dogs with lymphoma. Specifically, we will evaluate the bioavailability and epigenetic activity of SFN to assess it as a potential tumor suppressing agent in dogs with lymphoma.
Dogs will need a physical exam, complete blood count, serum biochemistry, urinalysis, cytology or histology of a lymph node and immunophenotyping (flow cytometry) to ensure eligibility for enrollment. The protocol includes two study groups (A and B). On Day 0, pre-SFN supplementation blood, urine and lymph node FNA samples will be collected for patients in both groups. Patients in group B will also undergo a lymph node punch biopsy under heavy sedation. All patients will subsequently receive SFN by mouth twice daily for 1 week. On Day 7, similar blood and tissue samples will be collected in both groups (post-SFN samples). Patients will then be deemed off-study and will be free to pursue mainstay chemotherapy treatment.
Dog owners will be responsible for the costs associated with the enrollment exam and diagnostics. The trial will cover all study related costs including exams, blood, urine and lymph node sampling, and SFN supplementation. Additionally, all patients will be given a financial credit at the completion of the study to offset the cost of pursuing further treatment at the OSU Veterinary Teaching Hospital. Detailed estimates of costs are available upon request.
Please do not hesitate to contact the OSU Oncology Service with any questions: Drs. Katie Curran, Shay Bracha, and Cyril Parachini-Winter are available at the main hospital number: (541) 737-4812
Canine Histiocytic Sarcoma Study
Histiocytic sarcoma (HS) is a relatively uncommon malignant form of cancer that has a poor response to therapy. Lomustine is one of the most effective chemotherapy agents for HS, with a reported response rate of 46%. A recent retrospective study reported a response rate of 58% when combination protocols (lomustine alternating with doxorubicin) were used for HS. In addition, studies on HS cell lines have found a significant increase in overall effectiveness of chemotherapy (doxorubicin) when combined with a bisphosphonate (zoledronate). The purpose of this study is to evaluate the safety and efficacy of a new chemotherapy protocol for the treatment of naïve canine HS patients. Patients enrolled in this clinical trial will receive either the standard of care chemotherapy (lomustine monotherapy) or a new combination protocol (lomustine alternating with doxorubicin + zoledronate). Compensation for participation in this clinical trial includes discounted exams fees and other serviceable fees. The cost for chemotherapy will not be covered by the clinical trial. Questions? Please contact Dr. Katie Curran or Dr. Shay Bracha: 541-737-4812
Canine Transitional Cell Carcinoma Study
Transitional cell carcinoma (TCC) is a form of cancer that arises from cells in the urinary bladder, urethra and prostate. Due to the location and proximity to vital structures, TCC treatment is often limited to chemotherapy and/or nonsteroidal anti-inflammatory agents (such as piroxicam). Both mitoxantrone and carboplatin are commonly used chemotherapeutics for the first-line treatment of canine TCC. Several studies in humans with advanced TCC of the urinary bladder have evaluated 5-fluorouracil in combination with traditional chemotherapy. The purpose of this study is to evaluate the safety and efficacy of a new chemotherapy protocol for the treatment of naïve canine TCC patients. Patients enrolled in this clinical trial will receive either mitoxantrone chemotherapy with piroxicam or a new combination protocol (mitoxantrone + 5-fluorouracil with piroxicam). Compensation for participation in this clinical trial includes discounted exams fees and other serviceable fees. The cost for chemotherapy will not be covered by the clinical trial. Questions? Please contact Dr. Katie Curran or Dr. Shay Bracha: 541-737-4812
Chemotherapy Study For Dogs With Lymphoid Cancer
Closed. Not accepting new patients.
Canine Fasting and Chemotherapy Study
Canine cancer patients treated with chemotherapy may have gastrointestinal side effects such as poor appetite and vomiting. Short-term fasting may decrease the risk of such side effects. We are recruiting dogs that will be administered chemotherapy (vincristine or carboplatin) as part of their cancer treatment. Research funding supports much of the expense of two chemotherapy treatments including exam fees, complete blood counts and chemotherapy administration fees.
Questions? Please contact Dr. Katie Curran or Dr. Shay Bracha: 541-737-4812.
Canine Osterosarcoma Study
Clinical trials for dogs with appendicular osteosarcoma that have not yet received any anti-cancer therapy. Both trials are funded to provide patients that qualify with standard of care therapy, either amputation followed by adjuvant carboplatin, or a novel oral therapeutic. Please contact the hospital Oncology Service for more details on inclusion criteria, trial specifics, and patient enrollment: 541-737-4812.
Canine Skin Tumor Study
Is computed tomography (CT) better than abdominal ultrasound for Mast Cell Tumor staging? Receive free Mast Cell Tumor staging and help us get closer to the answer! This study covers the cost of sedation, abdominal CT, and ultrasound of the liver and spleen with FNA cytology. The client will save over $700 per dog. Exclusion criteria includes dogs that have had prednisone or chemotherapy. Partial exclusion criteria (may not qualify for all discounts but still may receive some financial incentives) includes previous surgical excision of the tumor, immune-mediated diseases, coagulopathy, and/or endocrinopathy. This study uses the clinical imaging and cytology data, not the dogs themselves. The patients will still receive standard-of-care treatment determined by the OSU Oncology and Surgery Services. More information.
Questions? Do you have a dog owner interested in participation? Please call or schedule an appointment with the Small Animal Oncology or Soft Tissue Surgery Service at 541-737-4812.
Subaortic Stenosis Study
Dogs with subaortic stenosis are at increased risk for sudden death, and the benefits of standard therapy with Atenolol are unclear. The OSU Cardiology service is performing a study comparing the short-term effects of Atenolol and Sotalol on ventricular function, heart rate, and arrhythmias. We are recruiting young dogs with left basilar systolic murmurs for evaluation. Research funding supports much of the expense (~$650). Eligible dogs and owners are expected to pay exam fees (~$15 per visit). Study participants will be evaluated at 0, 2, and 5 weeks.
Questions? Please contact Dr. Katherine Scollan or Dr. Nicole LeBlanc: 541-737-4812.
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Study
Dogs with ARVC are at increased risk for sudden death, and some also develop systolic dysfunction which may progress to congestive heart failure. Sotalol is commonly used to treat arrhythmias in dogs with ARVC. However, the inotropic effects of sotalol have not been well-evaluated in dogs, and a reduction in contractility could precipitate heart failure in dogs affected with systolic dysfunction. The OSU Cardiology is performing a study evaluating the effects of Sotalol on systolic function in normal dogs and dogs with ARVC. We are recruiting adult Boxers (>4 years of age or with a clinical suspicion of arrhythmias) for screening for ARVC. Dogs who meet the criteria for ARVC on initial Holter monitor, and without echocardiographic evidence of overt left or right ventricular dysfunction, will be enrolled. Research funding supports much of the expense (~$265). Owners are expected to pay for Holter monitoring (~$300 x2) to establish the diagnosis and evaluate the response to anti-arrhythmic therapy. Study participants will be evaluated at 0 and 2 weeks.
Questions? Please contact Dr. Katherine Scollan or Dr. Nicole LeBlanc: 541-737-4812.
Recently Completed Clinical Trials
Canine Laryngeal Paralysis Study
Feline Hyperthyroidism Study
A study on CT imaging of the thyroid in awake cats. Completed June 2014. Abstract.
Feline Injection Site Sarcoma Study
A study of cats affected by, or suspected to be affected by, an injection site sarcoma. Completed June 2014. Abstract.
Platelet-Rich Plasma (PRP) Injection for Dogs with Hip Osteoarthritis
Giant Breed Growth Plate Study
Evaluation of bone development in large and giant breed dogs. Abstract.